Moleculin CEO buys 533,333 shares, gains new warrants

Moleculin Biotech, Inc. director, CEO and President Walter V. Klemp reported acquiring 533,333 shares of common stock in a public offering, together with Series I warrants to purchase 1,599,999 shares.

Rhea-AI Filing Summary

Moleculin Biotech, Inc. director, CEO and President Walter V. Klemp reported acquiring 533,333 shares of common stock in a public offering, together with Series I warrants to purchase 1,599,999 shares. The securities were bought at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants. Following these transactions, he directly holds 564,340 common shares and 1,926,335 Series I warrants, which are exercisable for common stock and expire on August 3, 2031.

Insider Trade Summary

Net Buyer: 533,333 shares

Net Buy 2 txns

Insider KLEMP WALTER V

Role CEO and President

Bought 533,333 shs

Type	Security	Shares	Price	Value
Grant/Award	Series I Warrants F1	1,599,999	--	--
Purchase	Common Stock F1	533,333	--	--

Holdings After Transaction: Series I Warrants — 1,926,335 contracts (Direct); Common Stock — 564,340 shares (Direct)

Footnotes (1)

1. F1. On August 3, 2026, the reporting person acquired 533,333 shares of common stock and Series I warrants to purchase 1,599,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering.

Key Figures

Common shares purchased: 533,333 shares Total common shares after transaction: 564,340 shares Series I warrants granted: 1,599,999 warrants +3 more

6 metrics

Common shares purchased 533,333 shares Shares of Moleculin Biotech common stock acquired on August 3, 2026 in a public offering

Total common shares after transaction 564,340 shares Direct holdings of common stock by Walter V. Klemp following the reported purchase

Series I warrants granted 1,599,999 warrants Series I warrants acquired on August 3, 2026, each exercisable into common stock

Total Series I warrants after transaction 1,926,335 warrants Direct holdings of Series I warrants by Walter V. Klemp after the grant

Combined purchase price $0.75 Per one share of common stock and three accompanying Series I warrants in the public offering

Warrant expiration date August 3, 2031 Expiration date of the reported Series I warrants

Key Terms

Series I Warrants, public offering, combined purchase price, underlying security

4 terms

Series I Warrants financial

"Series I Warrants to purchase 1,599,999 shares of common stock"

public offering financial

"three accompanying warrants in a public offering"

A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.

combined purchase price financial

"at a combined purchase price of $0.75 per one share"

underlying security financial

"underlying_security_title: "Common Stock" as the underlying security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Moleculin Biotech (MBRX) CEO Walter V. Klemp buy on August 3, 2026?

Walter V. Klemp acquired 533,333 shares of common stock and Series I warrants for 1,599,999 shares of Moleculin Biotech on August 3, 2026, as part of a public offering.

What price did Moleculin Biotech (MBRX) CEO pay in this Form 4 transaction?

The CEO paid a combined purchase price of $0.75 for one share of common stock and three accompanying Series I warrants in the public offering described in the Form 4.

How many Moleculin Biotech (MBRX) shares does the CEO own after the reported transactions?

After the reported transactions, Walter V. Klemp directly owns 564,340 shares of common stock of Moleculin Biotech, according to the post-transaction holdings disclosed in the Form 4.

How many Series I warrants does the Moleculin Biotech (MBRX) CEO hold after the grant?

Following the grant, Walter V. Klemp holds 1,926,335 Series I warrants, including 1,599,999 newly acquired warrants, each exercisable for common stock as disclosed in the filing.

When do the Moleculin Biotech (MBRX) Series I warrants held by the CEO expire?

The Series I warrants reported in the Form 4 have an expiration date of August 3, 2031, giving Walter V. Klemp several years to exercise them for common stock.

Was the Moleculin Biotech (MBRX) CEO’s Form 4 transaction part of a public offering?

Yes. The footnote states the CEO acquired 533,333 common shares and 1,599,999 Series I warrants at a combined price of $0.75 per unit in a public offering.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 04:17 PM Accepted by SEC EDGAR 08/05/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KLEMP WALTER V

(Last) (First) (Middle)

C/O MOLECULIN BIOTECH, INC.

5300 MEMORIAL DR., SUITE 950

(Street)

HOUSTON TEXAS 77007

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Moleculin Biotech, Inc. [ MBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		P		533,333	A	(1)	564,340	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series I Warrants	(1)	08/03/2026		A		1,599,999		08/03/2026	08/03/2031	Common Stock	1,599,999	(1)	1,926,335(1)	D

Explanation of Responses:

1. On August 3, 2026, the reporting person acquired 533,333 shares of common stock and Series I warrants to purchase 1,599,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering.

	/s/ Jonathan P. Foster by Power of Attorney	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)